AIM ImmunoTech Inc. Stock News

AIM ImmunoTech Inc (NYSE:AIM) said its clinical development collaborator Roswell Park Comprehensive Cancer Center has commenced patient enrollment in its phase 2 study evaluating Ampligen (rintatolimo

AIM ImmunoTech Inc (NYSE:AIM) announced that its Phase 2 study of Ampligen as a therapy for locally advanced pancreatic cancer (LAPC) has commenced after its trial protocol received approval from an I

AIM ImmunoTech Inc (NYSE:AIM) posted second-quarter financial results that showed ample cash on hand, giving the company scope to achieve multiple clinical and regulatory milestones. The Florida-base

Aimia, Inc. (OTCPK:AIMFF) Q2 2022 Earnings Conference Call August 12, 2022 8:30 AM ET Company Participants Steven Leonard - CFO Philip Mittleman - CEO & Director Michael Lehmann - President & Director

AIM ImmunoTech Inc (NYSE:AIM) has announced what it calls positive preliminary pilot study data from its ongoing Expanded Access Program (EAP) evaluating its investigational drug Ampligen as a therape

安普利近®（rintatolimod）显示出作为转移性和局部晚期胰腺癌（LACC）患者系统性化疗后潜在维持疗法的具有前景的活性

Gainers Tuesday Morning Corporation (NASDAQ: TUEM) rose 72.1% to $0.3420 in pre-market trading after dipping 30% on Wednesday. Tuesday Morning recently announced partnership with Intalytics for custo

Ampligen® (rintatolimod) has demonstrated promising activity as a potential maintenance therapy after systemic chemotherapy in patients with metastatic and locally advanced pancreatic cancer (LAPC)

向联邦法院提起诉讼，以迫使活动团体透露真实意图（包括对公司的潜在敌意收购）并防止该团体继续违反联邦证券法以及美国证券交易委员会（SEC）�

Live video webcast with moderated roundtable between members of the AIM ImmunoTech Management Team and Key Opinion Leader Professor C.H.J. van Eijck, MD PhD, of Erasmus Medical Center on Monday, July

Live video webcast with moderated roundtable between members of the AIM ImmunoTech Management Team and Key Opinion Leader Professor C.H.J. van Eijck, MD PhD, of Erasmus Medical Center on Monday, July

Gainers Versus Systems Inc. (NASDAQ: VS) rose 66% to $0.7802 in pre-market trading. Versus Systems, last month, received NASDAQ notification regarding minimum bid price deficiency. Histogen Inc.. (NA

Gainers Revelation Biosciences, Inc. (NASDAQ: REVB) rose 149.3% to $1.56 in pre-market trading after jumping 27% on Wednesday. Revelation Biosciences recently announced completion of dosing for Phas

Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) rose 92.9% to $0.2295 in pre-market trading. Allena Pharmaceuticals said it previously entered into at market issuance sales agreement with B. Ril

Gainers Kezar Life Sciences, Inc. (NASDAQ: KZR) rose 78% to $10.29 in pre-market trading after the company reported positive topline results from the MISSION Phase 2 clinical trial evaluating zetomi